The present study utilized thermogravimetry (TG) and optical emission spectroscopy with inductively coupled plasma (ICP/OES) to determine the amount of calcium in calcium citrate tablets, which are used for the treatment of osteoporosis. The samples were characterized using Fourier transform infrared spectroscopy (FTIR), termogravimetry/derivative thermogravimetry (TG/DTG), differential thermal analysis (DTA), differential scanning calorimetry (DSC) and X-ray diffraction (XRD). In the DTA and DSC curves obtained, both endo-and exothermic events were observed, which are indicative of dehydration and decomposition, respectively. The X-ray diffractograms showed that the samples present crystallinity. Additionally, peaks observed in the X-ray diffractograms indicate the presence of a calcium hydroxide residue due to the reaction between calcium oxide with moisture in the air. The calcium content obtained by TG from the tablet sample (17.77%) was similar to that obtained using ICP-OES (16.84%).
Introduction
Osteoporosis is defined as a reduction in bone mass accompanied by the deterioration of bone quality. These factors result in a reduction of bone strength and an increase the risk of fractures [1] . Two nutrients, calcium and vitamin D, are especially necessary for strong bones. Calcium is essential for the maintenance of bones, while vitamin D aids in the absorption of calcium [2] .
Calcium citrate (Figure 1 ) is the calcium salt of citric acid. It is generally used as a food additive, but it can also be used as a dietary calcium supplement. Calcium citrate is a white powder and is odorless and soluble in cold water [3, 4] . The determination of active ingredients using conventional procedures is difficult in some cases, as the active ingredients must be isolated. New techniques that provide information more quickly and more efficiently are needed to supplement or displace the analytical procedures that are currently used in drug analysis [5] . Thus, thermoanalytical techniques including TG, DTA and DSC have been characterized as important and effective tools in pharmaceutical analysis.
Studies on the thermal properties of zinc, bismuth and calcium citrate have been previously conducted [6] . The results indicated that the thermal decomposition of calcium citrate undergoes two dehydration steps with the elimination of 3 H 2 O, which is followed by a formation stage of the anhydrous compound. Subsequently, the formation step of calcium carbonate is followed by the formation of CaO at approximately 800 o C. All intermediates of thermal decomposition were characterized using absorption spectroscopy in the infrared region, and the data obtained were confirmed using thermogravimetry.
The thermal decomposition of calcium citrate tetrahydrate in both synthetic air and under a nitrogen atmosphere has been previously studied [7] . The results indicated that the decomposition occurred in five steps: two dehydration steps associated with the formation of the anhydrous compound; the thermal decomposition of calcium citrate with the formation of calcium carbonate; and finally, the decomposition step with the formation of calcium oxide.
The calcium content in chicken and quail egg shells was determined using thermogravimetry [8] . The final residues obtained by thermogravimetry were characterized using Fourier transform infrared (FTIR) absorption spectra, which indicated that they were composed of calcium oxide.
These results were confirmed using flame photometry and by a complexometric titration [8] .
Therefore, in this study, an analysis of the thermal behavior of a medication used in the treatment of osteoporosis by thermogravimetry (TG), Differential Thermal Analysis (DTA) and Differential Scanning Calorimetry (DSC) was completed. Additionally, the obtained results from the medication analysis were compared to the calcium content determined using thermogravimetry and optical emission spectroscopy with inductively coupled plasma (ICP-OES).
Experimental 2.1. Materials
The calcium citrate and the pharmaceutical formulation were purchased from a drugstore. Subsequently, the samples were weighed, pulverized in an agate mortar, packed in glass jars and placed in a desiccator.
For the analysis of calcium using ICP-OES, approximately 500 mg of the tablet was weighed in a porcelain capsule and calcined up to 600 o C for 4 hours. Concentrated nitric acid was added until the sample was completely dissolved and was subsequently diluted to 100 mL using deionized water. Analyses were performed in triplicate. Table 1 lists the drug, excipients and theoretical percentage of calcium in the pharmaceutical formulation.
Methods

Fourier transform infrared spectroscopy (FTIR)
The infrared spectra were recorded on a Thermo Nicolet, Nexus 470 model FTIR spectrophotometer in the spectral range of 4000-400 cm -1 using KBr pellets.
Thermogravimetry-Differential Thermal Analysis (TG-DTA)
The TG-DTA curves were recorded on a model DTG 60 thermal analysis system from Shimadzu. The purge gas air operated at a flow rate of 50 mL min -1 . The samples, in triplicate, were heated from room temperature to 900 °C. A heating rate of 10 ºC min -1 was utilized, with samples weighing approximately 7 mg. Alumina crucibles were used for obtaining the TG and DTA curves.
Differential Scanning Calorimetry (DSC)
The DCS curves were recorded on a model DSC 50H thermal analysis system from Shimadzu. Purge gas was nitrogen gas at a flow rate of 50 mL min -1 . The samples were heated from room temperature to 500 °C. A heating rate of 10 ºC min -1 was utilized, with samples weighing approximately 2 mg and closed aluminum crucibles were used during sample analysis.
X-ray diffraction
The X-ray powder patterns were obtained using a diffractometer XDR model -6000 Shimadzu with a proportion counter and pulse height discriminator. The Bragg-Brentano arrangement was adopted using Cu Kα radiation (=1.541 A), set at 38 kV and 20 mA, at a scanning speed of 2θ min -1 and using the powder method.
Inductively coupled plasma -optical emission spectroscopy (ICP -OES)
The calcium content in the samples was determined using inductively coupled plasma -optical emission spectroscopy (ICP -OES) on a 6300 model Shimadzu ICAP.
Results and Discussion
The FTIR spectra of the calcium citrate and the tablet samples are shown in Figure 2 .
The spectrum of the calcium citrate sample ( Figure  2a ) presents a broad band at 3482 cm -1 that is assigned to the stretching of the OH group ( OH), which results from hydration by water. These data are in agreement with the obtained TG curve (Figure 3 ). The spectrum also shows peaks at 1583 and 1441 cm -1 due the anti-symmetrical and symmetrical vibrations of the COO -group, respectively. The FTIR spectrum of the tablet sample (Figure 2b ) presents at 3451 cm -1 a band assigned to the stretching of the OH group ( OH), which results from hydration by water. These data are in agreement with the obtained TG curve (Figure 3) . A band observed at 2929 cm -1 indicates the stretching of the C-H bond, which is probably due to the Similar results have been previously reported when the formation of solid calcium ferrites from the thermal decomposition of mixtures of calcium citrate tetrahydrate and iron oxalate hexahydrated was studied [9] . The calculation performed using the TG curves revealed that 20.2% of elemental calcium was present in the sample of calcium citrate. o C) with the 18.8% mass loss most likely assigned to the thermal decomposition of the calcium citrate and excipients such as microcrystalline cellulose, magnesium stearate and croscarmellose sodium. According to [10] , the thermal decomposition of the croscarmellose sodium occurs between 180.0 and 600.0 o C with formation of Na 2 CO 3 , which is thermally stable up to 990.0 o C. Additionally, [11] The DTA curves of the calcium citrate and the tablet samples are shown in Figure 5 .
DTA curve of the calcium citrate sample three events are observed. The first endothermic peak observed between 37.9 and 89.7 o C and corresponds to dehydration, which was also observed in the TG curve. An exothermic peak is verified between 361.7 and 483.9 o C due the thermal decomposition of calcium citrate. Finally, an endotherm is observed when CaCO 3 decomposes in the range of 641.6 to 733.2 °C, which results in the formation of CaO. Similar results have been obtained previously when the thermal decomposition of calcium citrate tetrahydrate was studied [7] .
Initially, the DTA curve of the tablet sample shows two endothermic events. The first is observed between 64.7 and 108.6 o C and the second between 108.6 and 160.6 o C, and both events are due to dehydration. This information is in agreement with the mass losses observed in the TG curve. The exotherm that occurs in the range 313.3 at 382.3 o C can be attributed the thermal decomposition of the croscarmellose sodium present in the pharmaceutical formulation. There is also an exothermic peak observed between 419.9 and 502.3 o C, which is a result of the thermal decomposition of calcium citrate. Finally, the CaCO 3 is decomposed in the range of 674.7 to 729.3 °C with formation of CaO corresponding to an endothermic peak. ) corresponding to dehydration, which was also observed in both TG and DTA curves. Another endothermic peak is verified between 320.6 and 352.7 o C (H = 0.95 Kj mol -1 ), which is due the thermal decomposition of calcium citrate.
The DSC curve of the tablet sample shows initially two endothermic events. The first between 65.0 and 111. The X-ray powder patterns (Figure 7) show that the compounds presented crystalline structure, with peaks characteristic of calcium citrate (JCPDF:01-0008). Although the tablet sample contains silicon dioxide as an excipient, no peaks were observed, indicating the presence of this compound. Figure 8 shows the X-ray powder patterns of the intermediate compounds obtained by thermogravimetry at 550 °C from both the calcium citrate and the tablet samples. The diffractogram shows peaks indicative of calcium carbonate (JCPDF: 85-0849). This result is in agreement with the mass loss obtained from the TG curve, which indicates the thermal decomposition of anhydrous calcium citrate and the formation of CaCO 3 .
The diffractogram of the final residue obtained at 900 °C is shown in Figure 9 , and peaks are observed that are indicative of CaO (JCPDF: 77-2376) and Ca(OH) 2 (JCPDF: 76-0571). The formation of CaO is due to the thermal decomposition of calcium carbonate (CaCO 3(s)  CO 2(g) + CaO (s) ), and the presence of the calcium hydroxide is attributed to reaction between calcium oxide and water (CaO (s) + H 2 O (g)  Ca(OH) 2(s) ) as verified by [8] . The calcium content of the tablet samples with calcium citrate is provided in Table 2 , and this value can be determined from the loss of CO 2 observed in the last thermal event of the thermogravimetric curve.
There is an observed similarity between the results obtained by thermogravimetry and ICP-OES, which can be used to determine the percentage of calcium in the pharmaceutical formulations.
The calcium content obtained by TG for the tablet sample (17.77%) was similar to the result obtained by ICP-OES (16.84%). The theoretical value obtained from the pharmaceutical formulation was 17.87%, which demonstrates the agreement between the different instrumental techniques. These results show that thermogravimetry can be used to determine the level of calcium in pharmaceutical formulations while offering speed and minimal sample consumption. 
Conclusion
The TG and DTG curves provided information concerning the thermal behavior of these pharmaceutical formulations. The TG curves showed that the decomposition temperature of calcium citrate is lower than that of the tablet samples, which is due to the presence of different excipients in the pharmaceutical formulation. Both the DSC and DTA curves showed endothermic events, which are attributed to dehydration and decomposition, and exothermic peaks, which are the result of thermal decomposition of the calcium citrate and excipients. The X-ray powder patterns showed similarities, and the samples studied in this work present a crystalline phase. The results for the calcium content obtained by thermogravimetry are consistent with the data obtained by ICP-OES, which indicate the possibility of using these techniques to determine calcium in drugs containing calcium carbonate. Thermogravimetry offers advantages over other techniques that are currently used, including speed, operational simplicity and consumption of small amounts of sample.
